Protein Summary
This gene is one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene is located among several imprinted genes; however, this gene, as well as the pan-hematopoietic expression gene (PHEMX), escapes imprinting. This gene may play a role in malignancies and disease that involve this region. Several transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2014]
- ENST00000333256
- ENSP00000331087
- ENSG00000184281
- ENST00000380996
- ENSP00000370384
- ENST00000451491
- ENSP00000411224
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor binding site profile | 0.92 | ||
disease perturbation | 0.74 | ||
transcription factor | 0.71 | ||
cellular component | 0.58 | ||
small molecule perturbation | 0.58 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 6.51 (req: < 5)
Gene RIFs: 2 (req: <= 3)
Antibodies: 44 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 6.51 (req: >= 5)
Gene RIFs: 2 (req: > 3)
Antibodies: 44 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Term: 0
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0